Novaliq Announces More than 50% Patients Enrolled in CyclASol(R) Phase 3 Dry Eye Disease Trial ESSENCE-2
AsiaNet 89264
HEIDELBERG, Germany and CAMBRIDGE, Mass., April 28, 2021 /PRNewswire=KYODO JBN/ --
- Topline results expected in 2nd half 2021; 475 out of a 834 target patients
randomized in ESSENCE-2
- Enrollment for 12-month safety extension trial (ESSENCE-2 OLE) completed
- Phase 2B/3 Trial ESSENCE-1 Published in Cornea: The Journal of Cornea and
External Disease
Novaliq, a biopharmaceutical company focusing on first- and best-in-class
ocular therapeutics based on the unique EyeSol(R) water-free technology, today
announced that the second Phase 3 clinical trial evaluating CyclASol(R) to
treat the signs and symptoms of dry eye disease (DED) has randomized more than
50% out of 834 targeted patients, with top-line results expected in the 2nd
half of 2021.
The Phase 3 program for CyclASol(R) includes the already completed
multi-center, randomized, double-masked, vehicle-controlled trial in 328
patients (ESSENCE-1); the ongoing Phase 3 trial (ESSENCE-2) designed to
reconfirm efficacy results of the ESSENCE-1 trial; and a multi-center,
open-label, single-arm 12-month safety extension trial (ESSENCE-2 OLE). Results
from ESSENCE-2, if positive, will allow for a New Drug Application (NDA) filing
to the U.S Food and Drug Administration in 2022.
“We have been very successful in maintaining a good recruitment rate in the
ESSENCE-2 trial through careful selection and support of our clinical sites,
despite the COVID-19 pandemic environment,” said Sonja Krösser, Ph.D., Vice
President Clinical Development at Novaliq. “Patients had the opportunity to
roll-over into the open-label 12-month safety extension trial and we are
pleased to report that the ESSENCE-2 OLE trial has been completely enrolled
with a total of 200 participants. Achieving these two enrollment milestones
indicates that we are on track with the CyclASol(R) development program to file
our first NDA in 2022.”
CyclASol(R) is a topical, anti-inflammatory and immunomodulating ophthalmic
solution, containing 0.1% cyclosporine A in EyeSol(R), developed for the
treatment of DED. The unique water-free drug product is based on the EyeSol(R)
enhanced ocular bioavailability technology that allows for several fold higher
corneal penetration of cyclosporine A in comparison to water or oil-based
formulations [1]. This has led to the differentiated therapeutic profile of
CyclASol(R) with an early onset of efficacy within 2 weeks and significantly
improved tolerability.
The previous Phase 2B/3 clinical trial ESSENCE-1 which evaluated the efficacy,
safety, and tolerability of CyclASol(R) in patients with DED has been published
in Cornea: The Journal of Cornea and External Disease [2]. In this study,
CyclASol(R) demonstrated statistically significant improvements in
pre-specified endpoints for both signs and symptoms of DED as compared to its
vehicle after 4 weeks. Consistent with results from an earlier Phase 2 trial
[3], CyclASol(R) showed clinically meaningful improvements in both corneal and
conjunctival staining to monitor the ocular surface condition and improvements
in symptoms of dryness compared with those of its vehicle. Additionally, the
ESSENCE 1 trial demonstrated that reading speed improves with the corneal
staining reduction. Safety and tolerability in the trial were excellent with
outstanding application comfort scores which are usually only reported with
lubricating eye drops [2].
The ongoing ESSENCE-2 trial is a multicenter, randomized, double-masked,
vehicle-controlled clinical trial to assess efficacy, safety and tolerability
of CyclASol(R) for the treatment of signs and symptoms of DED. The trial is
planned to enroll approximately 834 subjects in about 25 U.S. clinical centers.
The primary endpoints of the trial are the change from baseline in total
corneal staining and in eye dryness score at day 29. The trial will again
include the assessment of reading speed as an objective and quantifiable
measurement of visual function. The company expects to publish topline data
from ESSENCE-2 in the 2nd half of 2021.
“We sincerely thank all patients, investigators and their local site personnel
for participating in this study, as well as the entire research and development
team in the U.S. and Heidelberg for their dedication and hard work to achieve
this important milestone, particularly under the additional complexities due to
the COVID-19 pandemic,” said Christian Roesky, Ph.D., CEO, Novaliq.
About Novaliq
Novaliq is a biopharmaceutical company focusing on the development and
commercialization of first- and best-in-class ocular therapeutics based on
EyeSol(R), the worldwide first water-free eye-drop technology. Novaliq offers
an industry-leading portfolio addressing today's unmet medical needs of
millions of patients with eye diseases. Novaliq GmbH is headquartered in
Heidelberg, Germany and Novaliq Inc. has an office in Cambridge, MA, USA. The
long-term shareholder is dievini Hopp BioTech holding GmbH & Co. KG, an active
investor in life and health sciences companies. More on www.novaliq.com.
Sources:
[1] Agarwal P et al. Semifluorinated alkane based systems for enhanced corneal
penetration of poorly soluble drugs. International Journal of Pharmaceutics 538
(2018) 119-129
[2] Sheppard JD et al. A Water-free 0.1% Cyclosporine A Solution for Treatment
of Dry Eye Disease: Results of the Randomized Phase II/III ESSENCE Study.
Cornea, January 2021, Publish Ahead of Print
https://doi.org/10.1097/ICO.0000000000002633
[3] Wirta DL et al. A Clinical Phase II Study to Assess Efficacy, Safety, and
Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye
Disease. Ophthalmology, Volume 126 (2019) 793-800
Logo - https://mma.prnewswire.com/media/1359866/Novaliq_Logo.jpg
Source: Novaliq GmbH
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。